IL-6 (Interleukin-6) and GP130 are part of the IL-6/JAK/STAT3 pathway that is involved in proliferation, survival, invasiveness and metastasis of tumor cells and in suppression of the anticancer immune response, and constitutes an attractive target for anti-cancer therapies. Here, IL6 is linked to cancer.